Aura Biosciences, Inc. Current Liabilities
Aura Biosciences, Inc. (AURA) had Current Liabilities of $19.56 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Liabilities, Current $19.56M.
- 2026-03-31: Liabilities, Current $16.71M.
- 2025-12-31: Liabilities, Current $18.38M.
- 2025-09-30: Liabilities, Current $18.82M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $19.56M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $16.71M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $18.38M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $18.82M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $14.85M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $12.16M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $14.91M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $14.71M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $10.55M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $9.66M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $12.36M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $10.89M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $8.89M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $8.11M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $10.46M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $9.96M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $5.81M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $5.00M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $7.36M 10-K · filed 2023-03-15 | $7.27M 10-K · filed 2022-03-23 |
| 2021-09-30 | $5.83M 10-Q · filed 2021-11-24 | |
| 2020-12-31 | $2.66M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |